Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Next Science Ltd ( (AU:NXS) ) is now available.
Next Science Limited reported a 7% decrease in revenues for the half-year ended June 30, 2025, amounting to USD 10,491,366. Despite the decline in revenue, the company managed to reduce its loss from ordinary activities by 20%, bringing it down to USD 4,687,973. No dividends were paid or proposed during this period. The net tangible assets per ordinary security also saw a decline, moving from 1.62 USD cents in the previous period to -0.84 USD cents in the current reporting period. This financial performance indicates challenges in maintaining revenue growth, yet shows some progress in cost management.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science Limited operates in the medical technology industry, focusing on developing and commercializing innovative solutions to address biofilm-related infections. The company is known for its proprietary XBIO technology, which targets biofilm-based infections, a significant concern in healthcare settings.
Average Trading Volume: 558,373
Technical Sentiment Signal: Sell
Current Market Cap: A$42.43M
For detailed information about NXS stock, go to TipRanks’ Stock Analysis page.